nach oben

Neurological Sciences

Erschienen in:

01.05.2012 | FICEF SYMPOSIUM: FROM FOOD TO MIGRAINE AND BACK

Migraine and metabolism

verfasst von: G. Casucci, V. Villani, D. Cologno, F. D’Onofrio

Erschienen in: Neurological Sciences | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a chronic disorder with complex pathophysiology involving both neuronal and vascular mechanisms. Migraine is associated with an increased risk of vascular disorders, such as stroke and coronary heart disease. Obesity and diabetes are metabolic disorders with a complex association with migraine. Insulin resistance, which represents the main causal factor of diseases involved in metabolic syndrome, is more common in patients with migraine. A better understanding of the relationship between metabolic syndrome and migraine may be of great clinical interest for migraine management.

Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ (2005) Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64:614–620PubMedCrossRef

Stang PE, Carson AP, Rose KM, Mo J, Ephross SA, Shahar E, Szklo M (2005) Headache, cerebrovascular symptoms, and stroke: the atherosclerosis risk in communities study. Neurology 64:1573–1577PubMedCrossRef

Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N (1997) Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 54:362–368PubMedCrossRef

Cook NR, Benseñor IM, Lotufo PA, Lee IM, Skerrett PJ, Chown MJ, Ajani UA, Manson JE, Buring JE (2002) Migraine and coronary heart disease in women and men. Headache 42:715–727PubMedCrossRef

Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283–291PubMedCrossRef

Davey G, Sedgwick P, Maier W, Visick G, Strachan DP, Anderson HR (2002) Association between migraine and asthma: matched case–control study. Br J Gen Pract 52:723–727PubMed

Sillanpaa M, Aro H (2000) Headache in teenagers: comorbidity and prognosis. Funct Neurol 15(suppl 3):116–121PubMed

Split W, Szydlowska M (1997) Headache in non-insulin dependent diabetes mellitus. Funct Neurol 12:327–332PubMed

Rainero I, Limone P, Ferrero M (2005) Insulin sensitivity is impaired in patients with migraine. Cephalalgia 25:593–597PubMedCrossRef

10.

Sattar N, Gaw A, Scherbakova O et al (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414–419PubMedCrossRef

11.

Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV; Strong Heart Study (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867

12.

Takahashi K, Bokura H, Kobayashi S, Iijima K, Nagai A, Yamaguchi S (2007) Metabolic syndrome increases the risk of ischemic stroke in women. Intern Med 46:643–648PubMedCrossRef

13.

Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssönen K, Salonen JT (2006) Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 37:806–811PubMedCrossRef

14.

Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, Cui R, Tanigawa T, Shimamoto T (2007) Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 38:1744–1751PubMedCrossRef

15.

Bigal E, Liberman JN, Lipton RB (2006) Obesity and migraine: a population study. Neurology 66:545–550PubMedCrossRef

16.

Aamodt AH, Stovner LJ, Midthjell K, Hagen K, Zwart JA (2007) Headache prevalence related to diabetes mellitus. The Head-HUNT study. Eur J Neurol 14:738–744PubMedCrossRef

17.

Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283–291PubMedCrossRef

18.

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G (2001) Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. BMJ 322:19–22PubMedCrossRef

19.

Casucci G, Villani V, Frediani F (2008) Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci 29:S123–S126PubMedCrossRef

20.

Medeiros FL, Medeiros PL, Valenca MM, Dodick D (2007) Simvastatin for migraine prevention. Headache 47:855–856PubMedCrossRef

21.

Buzzi MG, Sakas DE, Moskowitz MA (1989) Indomethacin and acetylsalicylic acid block neurogenic plasma proteins extravasation in rat dura mater. Eur J Pharmacol 165:251–258PubMedCrossRef

22.

Olesen J, Thomsen LL, Iversen H (1994) Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 15:149–153PubMedCrossRef

23.

Haffner SM (2006) Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 119(Suppl 1):S3–S9PubMedCrossRef

24.

National Cholesterol Education program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation 106:3143–3421

25.

Guldiken B, Guldiken S, Taskiran B, Koc G, Turgut N, Kabayel L, Tugrul A (2009) Migraine and metabolic syndrome. The Neurologist 15:55–58PubMedCrossRef

26.

Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349PubMedCrossRef

27.

Rasmussen BK, Jensen R, Schroll M, Olesen J (1991) Epidemiology of headache in a general population—a prevalence study. J Clin Epidemiol 44:1147–1157PubMedCrossRef

28.

Loevinger BL, Muller D, Alonso C, Coe CL (2007) Metabolic syndrome in women with chronic pain. Metabolism 56:87–93PubMedCrossRef

29.

Bigal ME, Lipton RB (2009) The epidemiology, burden and comorbidities of migraine. Neurol Clin 27:321–334PubMedCrossRef

30.

Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef

31.

Bigal ME, Lipton RB (2006) Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 67:252–257PubMedCrossRef

32.

Bigal ME, Tsang A, Loder E, Serrano D, Reed ML, Lipton RB (2007) Body mass index an episodic headaches: a population based study. Arch Intern Med 167:1964–1970PubMedCrossRef

33.

Horev A, Wirguin I, Lantsberg L, Ifergane G (2005) A high incidence of migraine with aura among morbidly obese women. Headache 45:936–938PubMedCrossRef

34.

Winter AC, Berger K, Buring JE, Kurth T (2009) Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia 29:269–278PubMedCrossRef

35.

Bond DS, Roth J, Nash JM, Wing RR (2011) Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment. Obes Rev 12(5):e362–e371PubMedCrossRef

36.

Peterlin BL, Rapaport AM, Kurth T (2009) Migraine and obesity: epidemiology, mechanisms, and implications. Headache 50:631–648PubMedCrossRef

37.

Peterlin BL, Rosso AL, Rapoport AM, Scher AI (2010) Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache 50:52–62PubMedCrossRef

38.

Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43(Suppl 3):S16–S20PubMed

39.

Sarchielli P, Alberti A, Baldi A, Coppola F, Rossi C, Pierguidi L, Floridi A, Calabresi P (2006) Pro-inflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 46:200–207PubMedCrossRef

40.

Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedCrossRef

41.

Gram DX, Hansen AJ, Wilken M, Elm T, Svendsen O, Carr RD, Ahrén B, Brand CL (2005) Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur J Endocrinol 153:963–969PubMedCrossRef

42.

Peterlin BL, Bigal ME, Tepper SJ, Urakaze M, Sheftell FD, Rapoport AM (2007) Migraine and adiponectin: is there a connection? Cephalalgia 27:435–446PubMedCrossRef

43.

Mohammad-Ali V, Pinkney JH, Coppack SW (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22:1145–1158CrossRef

44.

St-Pierre AC, Cantin B, Mauriege P et al (2005) Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ 172:1301–1305PubMedCrossRef

45.

Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef

46.

Aamodt AH, Stovner LJ, Midthjell K, Hagen K, Zwart JA (2007) Headache prevalence related to diabetes mellitus. The Head-HUNT study. Eur J Neurol 14:738–744PubMedCrossRef

47.

Mitsias PD, Ramadan NM, Levine SR, Schultz L, Welch KM (2006) Factors determining headache at onset of acute ischemic stroke. Cephalalgia 26:150–157PubMedCrossRef

48.

Cameron NE, Eaton SE, Cotter MA, Tesfaye S (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973–1988PubMedCrossRef

49.

Kihara M, Low PA (1995) Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol 32:180–185CrossRef

50.

Split W, Szydlowska M (1997) Headache in non-insulin dependent diabetes mellitus. Funct Neurol 12:327–332PubMed

51.

Oral contraceptives and stroke in young women (1975) Associated risk factors. JAMA 231:718–722CrossRef

52.

Elliott D (2008) Migraine and stroke: current perspectives. Neurol Res 30:801–812PubMedCrossRef

53.

Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, Launer LJ (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291:427–434PubMedCrossRef

54.

Kurth T, Slomke MA, Kase CS, Cook NR, Lee IM, Gaziano JM, Diener HC, Buring JE (2005) Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 64:1020–1026PubMedCrossRef

55.

MacClellan LR, Mitchell BD, Cole JW et al (2006) Familial aggregation of ischemic stroke in young women: the Stroke Prevention in Young Women Study. Genet Epidemiol 30:602–608PubMedCrossRef

56.

Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB (2009) Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology 72:1864–1871PubMedCrossRef

57.

Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283–291PubMedCrossRef

58.

Rose KM, Carson AP, Sanford CP et al (2004) Migraine and other headaches: associations with Rose angina and coronary heart disease. Neurology 63:2233–2239PubMedCrossRef

59.

Rose KM, Wong TY, Carson AP, Couper DJ, Klein R, Sharrett AR (2007) Migraine and retinal microvascular abnormalities: the Atherosclerosis Risk in Communities Study. Neurology 68:1694–1700PubMedCrossRef

60.

Chrysohoou C, Pitsavos C, Skoumas J et al (2007) The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population; the ATTICA study. Int J Cardiol 122:29–33PubMedCrossRef

61.

D’Amico D, Moschiano F, Leone M et al (1998) Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 18:618–621PubMedCrossRef

62.

Martinez-Sànchez P, Martìnez-Martìnez M, Fuentes B, Cuesta MV, Cuéllar-Gamboa L, Idrovo-Freire L, Fernàndez-Dominguez J, Tejedor E (2012) Migraine and hypercoagulable states in ischemic stroke. Cephalalgia 31(16):1609–1617

63.

D’andrea G, Bussone G, Allais G (2009) Efficacy of Ginkgolide in the prophylaxis of migraine with aura. Neurol Sci 30(suppl 1) S121–S124

64.

Akisn M, Kultursay N, Coker I, Huseynov A (1998) Platelet activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginko Biloba axtracts reduce PAF concentration in the brain. Biol Neonate 76(4):439–444

65.

Ramsden C, Douglas Mann J, Faurot KR et al (2011) Low omega-6 vs low omega- 6 plus high omega 3 dietary intervention for chronic daily headache: protocol for a randomized clinical trial. Trials 12:97PubMedCrossRef

Titel: Migraine and metabolism
verfasst von: G. Casucci
V. Villani
D. Cologno
F. D’Onofrio
Publikationsdatum: 01.05.2012
Verlag: Springer Milan
Erschienen in: Neurological Sciences / Ausgabe Sonderheft 1/2012
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-012-1047-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2012

Controversies in migraine: monotherapy

From neuroimaging to clinical setting: what have we learned from migraine pain?

Food as trigger and aggravating factor of migraine

Peripheral neuromodulation in chronic migraine

Polytherapy for migraine prophylaxis

Migraine and cardiovascular diseases

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Update Neurologie